| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1152/AJPHEART.01113.2007 |
| P698 | PubMed publication ID | 18055511 |
| P2093 | author name string | Jeffrey S Gilbert | |
| Michael J Ryan | |||
| Joey P Granger | |||
| Sydney R Murphy | |||
| Mona Sedeek | |||
| Babbette B LaMarca | |||
| P2860 | cites work | AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration | Q24290268 |
| Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor | Q24320710 | ||
| Eicosanoids in preeclampsia | Q28166550 | ||
| Soluble endoglin contributes to the pathogenesis of preeclampsia | Q28244053 | ||
| Cardiovascular and renal sympathetic activation by blood-borne TNF-alpha in rat: the role of central prostaglandins | Q28581223 | ||
| Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia | Q29615916 | ||
| Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor | Q33848380 | ||
| Long term mortality of mothers and fathers after pre-eclampsia: population based cohort study | Q33947553 | ||
| Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy | Q34182166 | ||
| Decreased endothelium-dependent vascular relaxation during reduction of uterine perfusion pressure in pregnant rat. | Q50514586 | ||
| Systemic hemodynamic and regional blood flow changes in response to chronic reductions in uterine perfusion pressure in pregnant rats. | Q50952787 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of interleukin 6. | Q51139503 | ||
| Hypertension produced by reductions in uterine perfusion in the pregnant rat: role of tumor necrosis factor-alpha. | Q51359651 | ||
| Effects of reduced uterine perfusion pressure on blood pressure and metabolic factors in pregnant rats. | Q51470693 | ||
| The relationship between abnormal glucose tolerance and hypertensive disorders of pregnancy in healthy nulliparous women. Calcium for Preeclampsia Prevention (CPEP) Study Group. | Q51567295 | ||
| Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein. | Q51574204 | ||
| Hyperinsulinemia in glucose-tolerant women with preeclampsia. A controlled study. | Q51581108 | ||
| Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. | Q51914188 | ||
| Sympathetic neural mechanisms in normal and hypertensive pregnancy in humans. | Q52862288 | ||
| Relation between circulating angiotensin II type 1 receptor agonistic autoantibodies and soluble fms-like tyrosine kinase 1 in the pathogenesis of preeclampsia. | Q52933863 | ||
| Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. | Q53600812 | ||
| Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. | Q53680742 | ||
| Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. | Q54130783 | ||
| Systemic hemodynamics and regional blood flow during chronic nitric oxide synthesis inhibition in pregnant rats. | Q54148277 | ||
| Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. | Q54661322 | ||
| Soluble fms-Like Tyrosine Kinase 1 Is Increased in Preeclampsia But Not in Normotensive Pregnancies with Small-for-Gestational-Age Neonates: Relationship to Circulating Placental Growth Factor | Q56619503 | ||
| First Trimester Placental Growth Factor and Soluble Fms-Like Tyrosine Kinase 1 and Risk for Preeclampsia | Q56619507 | ||
| Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1 | Q57105968 | ||
| Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial. | Q34514153 | ||
| Vitamins C and E and the risks of preeclampsia and perinatal complications | Q34518082 | ||
| Insulin resistance and its potential role in pregnancy-induced hypertension | Q35146337 | ||
| Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy | Q35699115 | ||
| Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question | Q35920602 | ||
| Role of the renin-angiotensin system in the pathogenesis of preeclampsia | Q36064478 | ||
| Preeclampsia: a renal perspective | Q36120940 | ||
| Circulating angiogenic factors in the pathogenesis and prediction of preeclampsia | Q36288766 | ||
| Clinical and biochemical evidence of endothelial cell dysfunction in the pregnancy syndrome preeclampsia | Q37421465 | ||
| Current topic: pre-eclampsia and the placenta | Q37492460 | ||
| Endothelin-1 triggers placental oxidative stress pathways: putative role in preeclampsia | Q40433104 | ||
| Vascular endothelial growth factor-mediated induction of manganese superoxide dismutase occurs through redox-dependent regulation of forkhead and IkappaB/NF-kappaB. | Q40526010 | ||
| Endoglin regulates nitric oxide-dependent vasodilatation | Q40597391 | ||
| Prostacyclin and thromboxane changes predating clinical onset of preeclampsia: a multicenter prospective study | Q40802999 | ||
| Glucose intolerance as a predictor of hypertension in pregnancy | Q41030613 | ||
| Preeclampsia: an endothelial cell disorder | Q41281924 | ||
| Importance of prostaglandins in hypertension during reduced uteroplacental perfusion pressure | Q41284596 | ||
| Nitric oxide and pregnancy | Q41449537 | ||
| Placental cytokines and the pathogenesis of preeclampsia | Q41452017 | ||
| CD105 prevents apoptosis in hypoxic endothelial cells | Q42441203 | ||
| Interleukin-1beta and neurogenic control of blood pressure in normal rats and rats with chronic renal failure | Q43495878 | ||
| Association of maternal endothelial dysfunction with preeclampsia | Q43553727 | ||
| Reduced uterine perfusion pressure during pregnancy in the rat is associated with increases in arterial pressure and changes in renal nitric oxide. | Q43576536 | ||
| Correlation between soluble endoglin, vascular endothelial growth factor receptor-1, and adipocytokines in preeclampsia | Q43739445 | ||
| High-salt diet enhances vascular reactivity in pregnant rats with normal and reduced uterine perfusion pressure | Q43744797 | ||
| Effect of angiotensin II synthesis blockade on the hypertensive response to chronic reductions in uterine perfusion pressure in pregnant rats. | Q43744800 | ||
| Vascular endothelial growth factor induces manganese-superoxide dismutase expression in endothelial cells by a Rac1-regulated NADPH oxidase-dependent mechanism | Q43771298 | ||
| Enhanced thromboxane synthesis during chronic reductions in uterine perfusion pressure in pregnant rats | Q44130345 | ||
| Insulin, insulin-like growth factor-1, and insulin resistance in women with pregnancy-induced hypertension | Q44141451 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human trophoblast cells | Q44320558 | ||
| Agonistic autoantibodies directed against the angiotensin II AT1 receptor in patients with preeclampsia | Q44413491 | ||
| Cytochrome P-450 inhibition attenuates hypertension induced by reductions in uterine perfusion pressure in pregnant rats | Q44752496 | ||
| L-arginine attenuates hypertension in pregnant rats with reduced uterine perfusion pressure | Q44760481 | ||
| TNF alpha concentrations and mRNA expression are increased in preeclamptic placentas | Q45102738 | ||
| Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia | Q45112360 | ||
| Tales from the crypt: beta-catenin in the development of juvenile polyps: commentary on the article by Iwamoto et al. on page 4. | Q45932850 | ||
| Potential role of endothelin-1 in normal and hypertensive pregnancies | Q46165905 | ||
| Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. | Q46339760 | ||
| Maternal autoantibodies from preeclamptic patients activate angiotensin receptors on human mesangial cells and induce interleukin-6 and plasminogen activator inhibitor-1 secretion | Q46344658 | ||
| Maternal and fetal modulators of lipid metabolism correlate with the development of preeclampsia | Q46359043 | ||
| Circulating factors as markers and mediators of endothelial cell dysfunction in preeclampsia | Q46433836 | ||
| Experimental preeclampsia produced by chronic constriction of the lower aorta: validation with longitudinal blood pressure measurements in conscious rhesus monkeys | Q46540991 | ||
| Increased depth of trophoblast invasion after chronic constriction of the lower aorta in rhesus monkeys | Q46733986 | ||
| Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness | Q46841539 | ||
| Enhanced endothelin synthesis by endothelial cells exposed to sera from pregnant rats with decreased uterine perfusion | Q46877931 | ||
| Women with preeclampsia have higher plasma endothelin levels than women with normal pregnancies | Q46878600 | ||
| Circulating angiogenic factors and the risk of preeclampsia | Q47217679 | ||
| Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women | Q47770771 | ||
| Amniotic vascular endothelial growth factor (VEGF) and nitric oxide (NO) in women with subsequent preeclampsia | Q47907082 | ||
| Insulin resistance and alterations in angiogenesis: additive insults that may lead to preeclampsia | Q47945074 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | pre-eclampsia | Q61335 |
| arterial hypertension | Q41861 | ||
| endothelium | Q111140 | ||
| pathophysiology | Q1135939 | ||
| P304 | page(s) | H541-50 | |
| P577 | publication date | 2007-11-30 | |
| P1433 | published in | American Journal of Physiology Heart and Circulatory Physiology | Q3193662 |
| P1476 | title | Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction | |
| P478 | volume | 294 |
| Q35151065 | 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model |
| Q36121867 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin differentially suppresses angiogenic responses in human placental vein and artery endothelial cells |
| Q40053408 | A Family Based Study of Carbon Monoxide and Nitric Oxide Signalling Genes and Preeclampsia |
| Q38126570 | A complicated role for the renin-angiotensin system during pregnancy: highlighting the importance of drug discovery |
| Q54361188 | A longitudinal study of circulating angiogenic and antiangiogenic factors and AT1-AA levels in preeclampsia. |
| Q33737551 | A new mouse model to explore therapies for preeclampsia |
| Q60730049 | A review of the associations between obstructive sleep apnea and hypertensive disorders of pregnancy and possible mechanisms of disease |
| Q57289167 | AMP-Activated Protein (AMPK) in Pathophysiology of Pregnancy Complications |
| Q55465043 | Advances in the renin angiotensin system focus on angiotensin-converting enzyme 2 and angiotensin-(1-7). |
| Q36593148 | Adverse Pregnancy Conditions, Infertility, and Future Cardiovascular Risk: Implications for Mother and Child. |
| Q38283938 | Advice on exercise for pregnant women with hypertensive disorders of pregnancy |
| Q51502394 | Aging attenuates the vasodilator response to relaxin. |
| Q36355165 | Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia |
| Q33523068 | Alteration of skin laser-Doppler flux response to local cooling in gestational hypertension |
| Q46342926 | Alterations of angiopoietin-related growth factor (Angptl6) during pregnancy and in pre-eclampsia |
| Q41091522 | Altered Maternal Plasma Glycogen Phosphorylase Isoenzyme BB as a Biomarker for Preeclampsia and Small for Gestational Age. |
| Q35885078 | An evaluation of the effects of hypertension during pregnancy on postpartum hearing as measured by transient-evoked otoacoustic emissions |
| Q36339336 | An increased population of regulatory T cells improves the pathophysiology of placental ischemia in a rat model of preeclampsia |
| Q38468746 | Analysis of gene expression identifies candidate markers and pathways in pre-eclampsia |
| Q27027039 | Angiotensin receptor agonistic autoantibodies and hypertension: preeclampsia and beyond |
| Q34154805 | Antihypertensive effects of inducible nitric oxide synthase inhibition in experimental pre-eclampsia |
| Q47146131 | Apelin as a novel drug for treating preeclampsia |
| Q50651982 | Assessment of ADMA, estradiol, and progesterone in severe preeclampsia. |
| Q50703172 | Assessment of endothelial function in pregnant women with preeclampsia and gestational diabetes mellitus by flow-mediated dilation of brachial artery. |
| Q50067730 | Association between the soluble epoxide hydrolase gene and preeclampsia |
| Q35715914 | Autoantibody-mediated IL-6-dependent endothelin-1 elevation underlies pathogenesis in a mouse model of preeclampsia |
| Q36050771 | Autoantibody-mediated angiotensin receptor activation contributes to preeclampsia through tumor necrosis factor-alpha signaling |
| Q36752130 | Beyond the threshold: an etiological bridge between hypoxia and immunity in preeclampsia |
| Q47159321 | Blood pressure self-monitoring in pregnancy: examining feasibility in a prospective cohort study. |
| Q34720155 | Brain cell apoptosis and enhancement of nervous excitability in pregnant rats with high plasma levels of homocysteine |
| Q35966390 | Cholinergic control of inflammation |
| Q43014003 | Chronic placental ischemia alters amniotic fluid milieu and results in impaired glucose tolerance, insulin resistance and hyperleptinemia in young rats |
| Q33799413 | Circulating and Vascular Bioactive Factors during Hypertension in Pregnancy |
| Q30409861 | Complement activation is critical for placental ischemia-induced hypertension in the rat. |
| Q47688833 | Continued Investigation Into 17-OHPC: Results From the Preclinical RUPP Rat Model of Preeclampsia |
| Q36110513 | Contribution of PARP to endothelial dysfunction and hypertension in a rat model of pre-eclampsia. |
| Q46323961 | Correlation of biochemical parameters and neonatal outcome in patients with gestational hypertension |
| Q36528411 | Cytochrome P450 subfamily 2J polypeptide 2 expression and circulating epoxyeicosatrienoic metabolites in preeclampsia |
| Q26830707 | Cytokines as key players in the pathophysiology of preeclampsia |
| Q92277390 | Determining Whether Hypertensive Status and Stress Level Are Associated With Inflammatory Markers |
| Q53407004 | Detrimental arterial inflammatory effect of microparticles circulating in preeclamptic women: ex vivo evaluation in human arteries. |
| Q34182374 | Differences and similarities in the transcriptional profile of peripheral whole blood in early and late-onset preeclampsia: insights into the molecular basis of the phenotype of preeclampsiaa |
| Q37200099 | Differential [Ca2+]i signaling of vasoconstriction in mesenteric microvessels of normal and reduced uterine perfusion pregnant rats |
| Q33872123 | Differential gene expression analysis of placentas with increased vascular resistance and pre-eclampsia using whole-genome microarrays |
| Q46819179 | Differential oxidative stress levels in mothers with preeclampsia delivering male and female babies |
| Q45384118 | Differential regulation of brain-derived neurotrophic factor in term and preterm preeclampsia |
| Q42976875 | Diverse mechanisms of endothelium-derived hyperpolarizing factor-mediated dilatation in small myometrial arteries in normal human pregnancy and preeclampsia |
| Q37996960 | Dynamic proteome in enigmatic preeclampsia: an account of molecular mechanisms and biomarker discovery |
| Q61844895 | ELABELA plasma concentrations are increased in women with late-onset preeclampsia |
| Q50660057 | Early pregnancy angiogenic proteins levels and pregnancy related hypertensive disorders. |
| Q92759792 | Effect of a black cumin (Nigella sativa) ethanol extract on placental angiotensin II type 1-receptor autoantibody (AT1-AA) serum levels and endothelin-1 (ET-1) expression in a preeclampsia mouse model |
| Q92354939 | Effect of pregnancy induced hypertension on adverse perinatal outcomes in Tigray regional state, Ethiopia: a prospective cohort study |
| Q33847163 | Effective prediction of preeclampsia by measuring serum angiotensin II, urinary angiotensinogen and urinary transforming growth factor β1. |
| Q53660798 | Effects of preeclamptic plasma on potassium currents of human umbilical vein endothelial cells. |
| Q34154020 | Effects of pregnancy, hypertension and nitric oxide inhibition on rat uterine artery myogenic reactivity |
| Q36825271 | Endoglin: a critical mediator of cardiovascular health |
| Q33652732 | Endothelial dysfunction and arterial stiffness in pre-eclampsia demonstrated by the EndoPAT method |
| Q34772464 | Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance |
| Q37244292 | Endothelin, kidney disease, and hypertension |
| Q34533218 | Endothelin-1 is not a Mechanism of IL-17 Induced Hypertension during Pregnancy. |
| Q37353537 | Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy |
| Q34727850 | Erythrocyte sodium/potassium ATPase activity in severe preeclampsia |
| Q50048635 | Estradiol decreases blood pressure in association with redox regulation in preeclampsia. |
| Q43050632 | Ethnic differences in resistance artery contractility of normotensive pregnant women. |
| Q51067918 | Evaluation of statin therapy on endothelial function in hypercholesterolemic rabbits by automatic measurement of arterial wall movement using ultrasound images. |
| Q37164277 | Evidence for immune cell involvement in decidual spiral arteriole remodeling in early human pregnancy |
| Q54456305 | Expression of antiangiogenic factors in the placental structures in pre-eclampsia. |
| Q46329620 | Favorable Maternal and Fetal Effects of Danshensu in an Experimental Mice Model of Preeclampsia |
| Q39223093 | From apelin to exercise: emerging therapies for management of hypertension in pregnancy |
| Q36268948 | Genetic, immune and vasoactive factors in the vascular dysfunction associated with hypertension in pregnancy |
| Q36369470 | Glycogen phosphorylase isoenzyme BB plasma concentration is elevated in pregnancy and preterm preeclampsia |
| Q35615008 | Heme Oxygenase-1 Attenuates Hypoxia-Induced sFlt-1 and Oxidative Stress in Placental Villi through Its Metabolic Products CO and Bilirubin |
| Q37312044 | Heme oxygenase in pregnancy and preeclampsia |
| Q37065405 | Heme oxygenase inhibition increases blood pressure in pregnant rats |
| Q48578792 | Heme oxygenase-1 is a potent inhibitor of placental ischemia-mediated endothelin-1 production in cultured human glomerular endothelial cells |
| Q36156828 | Hemolysis, elevated liver enzymes, and low platelet (HELLP) syndrome in a 26-year-old woman with cystic fibrosis: a case report. |
| Q49886917 | Hypertension and patterns of induced labor at term |
| Q39006055 | Hypertension in Pregnancy: Defining Blood Pressure Goals and the Value of Biomarkers for Preeclampsia |
| Q38400715 | Hypertension in pregnancy: natural history and treatment options |
| Q82743901 | Hypertension in women |
| Q38110492 | Hypertension: physiology and pathophysiology |
| Q89347707 | Hypertensive Disorders of Pregnancy |
| Q36079659 | Hypertensive disorders of pregnancy: Case definitions & guidelines for data collection, analysis, and presentation of immunization safety data |
| Q36409599 | Immune Mechanisms Linking Obesity and Preeclampsia |
| Q37854853 | Impact of dietary soy isoflavones in pregnancy on fetal programming of endothelial function in offspring |
| Q36725906 | In vitro and in vivo evidence for lack of endovascular remodeling by third trimester trophoblasts. |
| Q42610106 | Inching towards a targeted therapy for preeclampsia |
| Q84984877 | Increased Myogenic Responses of Resistance-Sized Mesenteric Arteries After Reduced Uterine Perfusion Pressure in Pregnant Rats |
| Q34904184 | Induction of heme oxygenase 1 attenuates placental ischemia-induced hypertension |
| Q47978128 | Inflammatory and procoagulant cytokine levels during pregnancy as predictors of adverse obstetrical complications |
| Q37315106 | Inflammatory cytokines in vascular dysfunction and vascular disease |
| Q37034439 | Inhibition of PPARγ during rat pregnancy causes intrauterine growth restriction and attenuation of uterine vasodilation |
| Q28388335 | Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases |
| Q50556867 | Iron status parameters in preeclamptic women |
| Q46320346 | L-arginine-nitric oxide pathway and oxidative stress in plasma and platelets of patients with pre-eclampsia |
| Q90049964 | LPS Induces Preeclampsia-Like Phenotype in Rats and HTR8/SVneo Cells Dysfunction Through TLR4/p38 MAPK Pathway |
| Q35956397 | Lack of Thromboxane Synthase Prevents Hypertension and Fetal Growth Restriction after High Salt Treatment during Pregnancy |
| Q33599045 | Levels of circulating endothelial cells in normotensive and severe preeclamptic pregnancies |
| Q34436853 | Lipid peroxidation is not associated with adipocytokines in preeclamptic women |
| Q34162448 | Maternal Serum Lipids in Women with Pre-eclampsia |
| Q42226011 | Maternal obesity and excess of fetal growth in pre-eclampsia |
| Q34619975 | Maternal plasma concentrations of sST2 and angiogenic/anti-angiogenic factors in preeclampsia. |
| Q33909572 | Maternal plasma soluble TRAIL is decreased in preeclampsia |
| Q34495512 | Maternal serum levels of TNF-alpha and IL-6 long after delivery in preeclamptic and normotensive pregnant women |
| Q34140082 | Maternally sequestered therapeutic polypeptides - a new approach for the management of preeclampsia |
| Q36910638 | Matrix metalloproteinases as drug targets in preeclampsia |
| Q52765849 | Mechanisms and Treatment of Halogen Inhalation-Induced Pulmonary and Systemic Injuries in Pregnant Mice. |
| Q37211008 | Mechanisms and potential therapies for preeclampsia |
| Q45828550 | Menstrual abnormalities and predisposition to pregnancy-related hypertensive disorders: a retrospective study |
| Q46319789 | Microvascular remodelling in preeclampsia: quantifying capillary rarefaction accurately and independently predicts preeclampsia |
| Q93156154 | Molecular Targets of Aspirin and Prevention of Preeclampsia and Their Potential Association with Circulating Extracellular Vesicles during Pregnancy |
| Q33349894 | Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia |
| Q51454988 | New Predictive Model at 11+0 to 13+6 Gestational Weeks for Early-Onset Preeclampsia With Fetal Growth Restriction. |
| Q35121453 | Nitric oxide dysregulation in the pathogenesis of preeclampsia among Ghanaian women |
| Q35721088 | Nitric oxide generation affects pro- and anti-angiogenic growth factor expression in primary human trophoblast |
| Q34909773 | Normal pregnancy- a state of insulin resistance |
| Q37465594 | Novel approaches for mechanistic understanding and predicting preeclampsia |
| Q42796975 | Ovarian vein thrombosis and mirror syndrome in association with sacrococcygeal teratoma |
| Q37449693 | Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats |
| Q39423454 | Pathophysiology and Current Clinical Management of Preeclampsia |
| Q26865332 | Pathophysiology of hypertension in pre-eclampsia: a lesson in integrative physiology |
| Q39208841 | Pharmacogenetics in the treatment of pre-eclampsia: current findings, challenges and perspectives |
| Q37451544 | Placental Ischemia and Resultant Phenotype in Animal Models of Preeclampsia |
| Q46043654 | Placental and fetal hemodynamics after labetalol or pindolol in a sheep model of increased placental vascular resistance and maternal hypertension. |
| Q36309148 | Placental and vascular adaptations to exercise training before and during pregnancy in the rat |
| Q37483999 | Placental ischemia and breast cancer risk after preeclampsia: tying the knot |
| Q37114991 | Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections |
| Q88542480 | Placental ischemia-stimulated T-helper 17 cells induce preeclampsia-associated cytolytic natural killer cells during pregnancy |
| Q36974170 | Placental oxidative stress alters expression of murine osteogenic genes and impairs fetal skeletal formation |
| Q56794524 | Plasma and placental nitric oxide levels in women with and without pre-eclampsia living at different altitudes |
| Q34222231 | Plasma from preeclamptic women increases blood-brain barrier permeability: role of vascular endothelial growth factor signaling |
| Q36141421 | Postpartum Vascular Dysfunction in the Reduced Uteroplacental Perfusion Model of Preeclampsia |
| Q37180109 | Predictive factors for preeclampsia in pregnant women: a Receiver Operation Character approach |
| Q92994624 | Preeclampsia link to gestational hypoxia |
| Q36112505 | Preeclampsia serum upregulates CD40/CD40L expression and induces apoptosis in human umbilical cord endothelial cells |
| Q27000388 | Preeclampsia, hypoxia, thrombosis, and inflammation |
| Q43744904 | Preeclampsia-associated stresses activate Gadd45a signaling and sFlt-1 in placental explants |
| Q104137018 | Preeclampsia: Linking Placental Ischemia with Maternal Endothelial and Vascular Dysfunction |
| Q26800272 | Preeclampsia: long-term consequences for vascular health |
| Q33883127 | Pregnancy-induced hypertension is accompanied by decreased number of circulating endothelial cells and circulating endothelial progenitor cells |
| Q36919139 | Prepregnancy Vascular Dysfunction in Women who Subsequently Develop Hypertension During Pregnancy |
| Q35525644 | Preterm birth and long-term maternal cardiovascular health |
| Q37589007 | Primary hypertension and special aspects of hypertension in older children and adolescents |
| Q33983395 | Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy |
| Q38691672 | Proliferation of endogenous regulatory T cells improve the pathophysiology associated with placental ischaemia of pregnancy |
| Q34404445 | Recent insights into the pathophysiology of preeclampsia |
| Q35707881 | Receptor-activating autoantibodies and disease: preeclampsia and beyond |
| Q35683468 | Recombinant vascular endothelial growth factor 121 attenuates autoantibody-induced features of pre-eclampsia in pregnant mice |
| Q33666742 | Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension |
| Q35395483 | Reduced NO signaling during pregnancy attenuates outward uterine artery remodeling by altering MMP expression and collagen and elastin deposition |
| Q34429164 | Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic conditions in rat placental villous explants |
| Q38740120 | RhoB/ROCK mediates oxygen-glucose deprivation-stimulated syncytiotrophoblast microparticle shedding in preeclampsia |
| Q33793455 | Risk factors and mediators of the vascular dysfunction associated with hypertension in pregnancy |
| Q47799476 | Role of Nitric Oxide Synthase on Blood Pressure Regulation and Vascular Function in Pregnant Rats on a High-Fat Diet |
| Q35086662 | Role of Reactive Oxygen Species During Hypertension in Response to Chronic Antiangiogenic Factor (sFlt-1) Excess in Pregnant Rats |
| Q28571017 | Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats |
| Q26828020 | Role of endothelin in uteroplacental circulation and fetal vascular function |
| Q37449704 | Role of reactive oxygen species in hypertension produced by reduced uterine perfusion in pregnant rats |
| Q49813818 | Selective inhibition of 20-hydroxyeicosatetraenoic acid lowers blood pressure in a rat model of preeclampsia |
| Q45350029 | Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia |
| Q37323529 | Sildenafil attenuates placental ischemia-induced hypertension |
| Q36824048 | Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells |
| Q42794846 | Surviving the remodel: the impact of hypertension during pregnancy |
| Q35836181 | Syncytiotrophoblast Extracellular Vesicles from Pre-Eclampsia Placentas Differentially Affect Platelet Function |
| Q42640559 | Systemic and placental α-klotho: Effects of preeclampsia in the last trimester of gestation |
| Q37729072 | The Endothelin Type A Receptor as a Potential Therapeutic Target in Preeclampsia |
| Q47178980 | The Mediterranean diet adherence by pregnant women delivering prematurely: association with size at birth and complications of prematurity. |
| Q52715243 | The Role of Interleukin-10 in the Pathophysiology of Preeclampsia. |
| Q36716822 | The Role of PPARs in Placental Immunology: A Systematic Review of the Literature |
| Q34150192 | The anti-aging factor α-klotho during human pregnancy and its expression in pregnancies complicated by small-for-gestational-age neonates and/or preeclampsia |
| Q34295822 | The heme oxygenases: important regulators of pregnancy and preeclampsia |
| Q38664824 | The prediction of late-onset preeclampsia: Results from a longitudinal proteomics study |
| Q50102668 | The profiles of soluble adhesion molecules in the "great obstetrical syndromes". |
| Q54599986 | The relationship between circulating endothelin-1, soluble fms-like tyrosine kinase-1 and soluble endoglin in preeclampsia. |
| Q37362748 | The role of the L-arginine-nitric oxide pathway in preeclampsia |
| Q33668328 | The therapeutic potential of antioxidants, ER chaperones, NO and H2S donors, and statins for treatment of preeclampsia |
| Q54981809 | Therapeutic Effect of Long-Term Epidural Block in Rats with Pregnancy Induced Hypertension. |
| Q48284671 | Therapeutic benefit of mesenchymal stem cells in pregnant rats with angiotensin receptor agonistic autoantibody-induced hypertension: Implications for immunomodulation and cytoprotection. |
| Q84585891 | Toll-like receptor 3 activation during pregnancy elicits preeclampsia-like symptoms in rats |
| Q42380693 | Upregulation of P53 promoted G1 arrest and apoptosis in human umbilical cord vein endothelial cells from preeclampsia. |
| Q54423890 | VEGF deficit is involved in endothelium dysfunction in preeclampsia. |
| Q90011558 | Vascular Endothelial Growth Factor Delivery to Placental Basal Plate Promotes Uterine Artery Remodeling in the Primate |
| Q89492142 | Vascular Endothelial Growth Factor-121 Administration Mitigates Halogen Inhalation-Induced Pulmonary Injury and Fetal Growth Restriction in Pregnant Mice |
| Q33781354 | Vascular and cellular calcium in normal and hypertensive pregnancy |
| Q38124456 | Vascular dysfunction in preeclampsia |
| Q54672383 | Vascular endothelial growth factor, soluble fms-like tyrosine kinase 1, and the severity of coronary artery disease. |
| Q36699839 | Vitamin D supplementation improves pathophysiology in a rat model of preeclampsia |
| Q51294484 | Vitamin D supplementation reduces some AT1-AA-induced downstream targets implicated in preeclampsia including hypertension. |
Search more.